- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05542056
Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia (PROPHECY)
Urinary Prostaglandin as a Potential Predictive Marker for Thiazide-induced Hyponatremia: a Prospective Cohort Study (The PROPHECY Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Thiazides and thiazide-like diuretics are one of the five major classes of antihypertensive drugs. They act by inhibiting the apical Na+-Cl- -cotransporter in the distal convoluted tubules of the kidneys. Thiazides and thiazide-like diuretics often cause adverse effects, importantly a drop in plasma sodium levels that is called thiazide-induced hyponatremia (TIH). Data suggest a crucial role of urinary PGE2 in water reabsorption. Since urinary PGE2 concentrations were higher in patients with TIH, quantification of urinary PGE2 prior and after thiazide initiation might allow identification of patients at risk for TIH, presenting PGE2 as a potential novel predictive marker for the development of TIH.
This study is to investigate whether urinary PGE2 concentration at baseline (prior to thiazide initiation) is associated with the development of TIH within the first four weeks of treatment. Hospitalized and ambulatory patients in whom a thiazide or thiazide-like diuretic will be newly prescribed are screened for inclusion.
The study procedure contains the screening and inclusion, visit 1 before thiazide initiation, visit 2 4 weeks (+/-7days) after thiazide initiation and a 3-months follow-up (visit 3). An additional visit (visit 2.1) will only be added in case of a dose change of the thiazide or thiazide-like diuretic (4 weeks +/- 7 days after the dose change). The 2 hours- challenge is optional if the patient agrees to additional testing.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Julia Beck, Dr. med.
- Phone Number: +41 61 328 54 37
- Email: julia.beck@usb.ch
Study Locations
-
-
-
Basel, Switzerland, 4031
- Recruiting
- University Hospital Basel, Endocrinology, Diabetes and Metabolism
-
Contact:
- Julia Beck, Dr. med.
- Phone Number: +41 61 328 54 37
- Email: julia.beck@usb.ch
-
Principal Investigator:
- Julia Beck, Dr. med.
-
Sub-Investigator:
- Sophie Monnerat
-
Sub-Investigator:
- Thilo Burkard, Dr. med.
-
Sub-Investigator:
- Ewout J. Hoorn, Prof. Dr. med.
-
Sub-Investigator:
- Michael Mayr, PD Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Newly prescribed thiazide or thiazide-like diuretic
- ≥ 18 years of age
- Informed Consent as documented by signature
Exclusion Criteria:
- Intake of thiazide or thiazide-like diuretic in the preceding month
- Hyponatremia (plasma sodium <135 mmol/L) at baseline
- Acute infectious / inflammatory disease (CRP ≥ 20 mg/L [1, 11])
- Symptomatic urinary tract infection
- Chronic treatment with NSAID and / or NSAID intake 48 hours prior to urine sampling at visit 1 and 2 (intake of acetylsalicylic acid will be no exclusion criteria)
- End of life care, no informed consent or inability to follow the procedures of the study, e.g., due to language barriers, psychological disorders, dementia
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with newly prescribed thiazide or thiazide-like diuretic
As the study population of this observational study shall be as representative as possible all patients with a new thiazide or thiazide-like diuretic regardless of the indication, co-morbidities and co-medication can be included.
|
Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of hyponatremia (plasma sodium <135 mmol/L)
Time Frame: Within the first four weeks of treatment (at visit 2)
|
Occurrence of hyponatremia (plasma sodium <135 mmol/L)
|
Within the first four weeks of treatment (at visit 2)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in urinary Prostaglandin- concentration
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in urinary Prostaglandin E2 (PGE2) and metabolite (PGE2M)- concentration
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in the expression of proteins involved in sodium and water transport
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in the expression of proteins involved in sodium and water transport (AQP2, Prostaglandin transporter (PGT) and NCC) in urinary extracellular vesicles in spot urine (second morning urine)
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in systolic and diastolic blood pressure
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in systolic and diastolic blood pressure
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in heart rate
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in heart rate
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in body weight
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in body weight
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in daily fluid intake
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in daily fluid intake
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in Bioelectrical impedance analysis (BIA)
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in Bioelectrical impedance analysis (BIA)
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in plasma sodium
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in plasma sodium
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in urine sodium
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in urine sodium
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in potassium
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in potassium
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in chloride
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in chloride
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in creatinine
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in creatinine
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in urea
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in urea
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in uric acid
Time Frame: Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in uric acid
|
Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks
|
Change in general well-being
Time Frame: Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Change in general well-being rated on a visual analogue scale reaching from 0 to 10
|
Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months
|
Incidence of hyponatremia
Time Frame: Between baseline and visit 3, approximately 3 months
|
Incidence of hyponatremia
|
Between baseline and visit 3, approximately 3 months
|
Incidence of falls
Time Frame: Between baseline and visit 3, approximately 3 months
|
Incidence of falls
|
Between baseline and visit 3, approximately 3 months
|
Incidence of fractures
Time Frame: Between baseline and visit 3, approximately 3 months
|
Incidence of fractures
|
Between baseline and visit 3, approximately 3 months
|
Incidence of hospitalization due to any cause
Time Frame: Between baseline and visit 3, approximately 3 months
|
Incidence of hospitalization due to any cause
|
Between baseline and visit 3, approximately 3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mirjam Christ-Crain, Prof. Dr. med., University Hospital Basel, Endocrinology, Diabetes and Metabolism
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-01241; kt21ChristCrain3
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thiazide-induced Hyponatremia (TIH)
-
Hospital Italiano de Buenos AiresSociedad Argentina de Hipertension Arterial (SAHA)CompletedThiazide Diuretics Induced HyponatremiaArgentina
-
Yale UniversityCompletedExercise Induced HyponatremiaUnited States
-
The University of Texas Health Science Center,...TerminatedBronchopulmonary Dysplasia | Hyponatremia on DiureticsUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedHyponatremia | Inappropriate ADH Syndrome | Water Intoxication | Water-electrolyte ImbalanceGermany
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States
Clinical Trials on Data and biosample collection
-
Imperial College LondonCancer Research UKRecruitingGastric Adenocarcinoma | Oesophageal AdenocarcinomaUnited Kingdom
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
Neurological Institute of AthensKing's College London; Uppsala University; Rabin Medical Center; University of... and other collaboratorsRecruitingEpilepsy | Healthy | Sleep Disorder | Dementia | Alzheimer Disease | Circadian Rhythm DisordersIsrael, United Kingdom, Greece, Spain
-
Care Management PlusCompletedHealth Information Technology | Nurse Based Care ManagementUnited States
-
University Hospital, Basel, SwitzerlandRecruitingInfections With CPBSwitzerland
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
M.D. Anderson Cancer CenterUnknownPediatric CancerUnited States
-
GlaxoSmithKlineCompletedInfections, StreptococcalRomania, Slovenia, Poland, Lithuania, Estonia
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting